These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 21455660)

  • 1. A patient undergoing chronic dialysis whose renal anemia was successfully corrected by treatment with cinacalcet.
    Oshiro Y; Tanaka H; Okimoto N
    Clin Exp Nephrol; 2011 Aug; 15(4):607-10. PubMed ID: 21455660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients.
    Ballinger AE; Palmer SC; Nistor I; Craig JC; Strippoli GF
    Cochrane Database Syst Rev; 2014; 2014(12):CD006254. PubMed ID: 25490118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Retrospective assessment of effective and safety of cinacalcet for the treatment of secondary hyperparathyroidism depending on basal iPTH level].
    Mercadal Orfila G; Blasco Mascaró I
    Farm Hosp; 2012; 36(1):11-5. PubMed ID: 21514862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial.
    Parfrey PS; Chertow GM; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Dehmel B; Trotman ML; Modafferi DM; Goodman WG
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4834-44. PubMed ID: 24108314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cinacalcet for managing secondary hyperparathyroidism in dialysis patients in clinical practice in Belgium: a 16-month observational study (ECHO-B).
    Debelle F; Meeus G; Dratwa M; Maes B; Vanholder R; Albert A; Schutyser E; Jadoul M
    Acta Clin Belg; 2013; 68(4):275-81. PubMed ID: 24455797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Secondary Hyperparathyroidism Treatment on Improvement in Anemia: Results from the MBD-5D Study.
    Tanaka M; Yoshida K; Fukuma S; Ito K; Matsushita K; Fukagawa M; Fukuhara S; Akizawa T
    PLoS One; 2016; 11(10):e0164865. PubMed ID: 27764168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study.
    Tentori F; Wang M; Bieber BA; Karaboyas A; Li Y; Jacobson SH; Andreucci VE; Fukagawa M; Frimat L; Mendelssohn DC; Port FK; Pisoni RL; Robinson BM
    Clin J Am Soc Nephrol; 2015 Jan; 10(1):98-109. PubMed ID: 25516917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism.
    Susantitaphong P; Vadcharavivad S; Susomboon T; Singhan W; Dumrongpisutikul N; Jakchairoongruang K; Eiam-Ong S; Praditpornsilpa K
    Ren Fail; 2019 Nov; 41(1):326-333. PubMed ID: 31014177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of cinacalcet on bone mineral density and bone markers in hemodialysis patients with secondary hyperparathyroidism.
    Tsuruta Y; Okano K; Kikuchi K; Tsuruta Y; Akiba T; Nitta K
    Clin Exp Nephrol; 2013 Feb; 17(1):120-6. PubMed ID: 22833360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of hypercalcemia after renal transplantation.
    Torregrosa JV; Barros X
    Nefrologia; 2013 Nov; 33(6):751-7. PubMed ID: 24241361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity.
    Frazão JM; Messa P; Mellotte GJ; Geiger H; Hagen EC; Quarles LD; Kerr PG; Baños A; Dehmel B; Urena P
    Clin Nephrol; 2011 Sep; 76(3):233-43. PubMed ID: 21888861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
    Lindberg JS; Culleton B; Wong G; Borah MF; Clark RV; Shapiro WB; Roger SD; Husserl FE; Klassen PS; Guo MD; Albizem MB; Coburn JW
    J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of cinacalcet treatment on bone mineral metabolism, anemia parameters, left ventricular mass index and parathyroid gland volume in hemodialysis patients with severe secondary hyperparathyroidism.
    Torun D; Yildiz I; Micozkadioglu H; Nursal GN; Yigit F; Ozelsancak R
    Saudi J Kidney Dis Transpl; 2016 Jan; 27(1):15-22. PubMed ID: 26787561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Secondary hyperparathyroidism and anemia. Effects of a calcimimetic on the control of anemia in chronic hemodialysed patients. Pilot Study].
    Mpio I; Boumendjel N; Karaaslan H; Arkouche W; Lenz A; Cardozo C; Cardozo J; Pastural-Thaunat M; Fouque D; Silou J; Attaf D; Laville M
    Nephrol Ther; 2011 Jul; 7(4):229-36. PubMed ID: 21353659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
    Palmer SC; Mavridis D; Johnson DW; Tonelli M; Ruospo M; Strippoli GFM
    Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
    Dong BJ
    Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Timing of parathyroidectomy for tertiary hyperparathyroidism with end-stage renal disease: A cost-effectiveness analysis.
    McManus C; Oh A; Lee JA; Hur C; Kuo JH
    Surgery; 2021 Jan; 169(1):94-101. PubMed ID: 32732069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal impact of calcimimetics on the management of hyperparathyroidism in chronic dialysis.
    Brunaud L; Ngueyon Sime W; Filipozzi P; Nomine-Criqui C; Aronova A; Zarnegar R; Kessler M; Frimat L; Ayav C
    Surgery; 2016 Jan; 159(1):183-91. PubMed ID: 26476826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of cinacalcet on parathyroid hormone level in hypercalcemic hyperparathyroidism of patients with renal transplantation].
    Vaquero E; Esteban de la Rosa RJ; Oliva N; Fernández Castillo R; Fernández Gallegos R; Bravo Soto J
    Med Clin (Barc); 2012 Apr; 138(8):323-6. PubMed ID: 21492884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.